---
title: "CEL-SCI notifies availability of Multikine Phase 3 confirmatory study launch release"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292485087.md"
description: "CEL-SCI announced the launch of a global Phase 3 confirmatory study for Multikine in newly diagnosed, resectable head and neck cancer. The trial targets 212 patients with low/zero PD-L1 expression across the US, Europe, Asia, and South America. Designed to confirm a 0.34 hazard ratio on overall survival, pre-surgical tumor response data may support an FDA accelerated approval filing."
datetime: "2026-07-13T12:01:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292485087.md)
  - [en](https://longbridge.com/en/news/292485087.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292485087.md)
generator: "portal-rs"
---

# CEL-SCI notifies availability of Multikine Phase 3 confirmatory study launch release

-   CEL-SCI published a release launching a global Phase 3 confirmatory, registration-enabling study of Multikine for newly diagnosed, resectable head and neck cancer. \* Trial targets 212 patients with low or zero PD-L1 expression and no clinical lymph node involvement; enrollment planned across the U.S., Europe, Asia, later South America. \* Study design targets about 97% power to confirm a 0.34 hazard ratio on overall survival; prior target subgroup showed 73% 5-year survival vs 45%. \* Pre-surgical tumor response endpoints may support an FDA accelerated or conditional approval filing while overall survival follow-up continues. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607130800BIZWIRE\_USPR\_\_\_\_\_20260713\_BW392922) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CVM.US](https://longbridge.com/en/quote/CVM.US.md)

## Related News & Research

- [CEL-SCI CEO Geert Kersten acquires 100,000 common shares valued at $138,000](https://longbridge.com/en/news/297046035.md)
- [UNITED FRANCHISE GROUP REPORTS ROBUST GROWTH IN FIRST HALF OF 2026](https://longbridge.com/en/news/298936084.md)
- [Aliko Scientific Launches Probantes in Brazil and Establishes a New Molecular Diagnostic Development and Commercial Platform for South America](https://longbridge.com/en/news/299002010.md)
- [Elicera Therapeutics advances ELC-301 into Phase IIa at highest dose in B-cell lymphoma trial](https://longbridge.com/en/news/298410878.md)
- [Sanlam subsidiary director T Fick sells shares worth R 610,755.60](https://longbridge.com/en/news/299061762.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**